查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
中樞神經系主導療藥的全球市場 (～2027年):各藥物類別、用途、給藥途徑、終端用戶、流通管道、地區的競爭、預測、機會
市場調查報告書
商品編碼
1121072

中樞神經系主導療藥的全球市場 (～2027年):各藥物類別、用途、給藥途徑、終端用戶、流通管道、地區的競爭、預測、機會

Global Central Nervous System Therapeutics Market By Drug Class By Application By Route of Administration By End Users By Distribution Channel By Region, Competition Forecast & Opportunities, 2027
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球中樞神經系主導療藥的市場，在預測期間的2023年到2027年之間預計以強的年複合成長率成長。

中樞神經系統疾病的盛行率上升，及中樞神經系統疾病的治療、診斷的進步等要素促進該市場的需求。還有政府當局，醫療制度，非營利團體，市場相關人員對神經病變相關意識提升的措施也預期更加推動在預測期間內的市場成長。

本報告提供全球中樞神經系主導療藥的市場調查，市場概要，市場規模的變化、預測，各種區分、各地區/主要國家的明細，市場的各種影響因素的分析，競爭環境，市場佔有率，主要企業簡介等彙整資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19:對全球中樞神經系主導療藥市場的影響

第4章 摘要整理

第5章 VOC (客戶的迴響)

第6章 全球中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物(止痛藥、麻醉劑、抗痙攣藥、抗癲癇藥、抗帕金森藥、其他)
    • 各用途(神經血管疾病、心理健康和外傷、神經退化性疾病、感染疾病、中樞神經系統癌症、其他)
    • 各給藥途徑(口服、非口服、其他)
    • 各終端用戶(醫院、診療所、診斷實驗室、其他)
    • 各流通管道(醫院藥局、線上藥局、零售藥局)
    • 各企業
    • 各地區(北美、歐洲、亞太地區、南美、中東&非洲)
  • 產品市場地圖

第7章 北美的中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各流通管道
    • 各國
  • 各國分析

第8章 歐洲的中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各流通管道
    • 各國
  • 各國分析

第9章 亞太地區的中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各流通管道
    • 各國
  • 各國分析

第10章 中東及非洲的中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各流通管道
    • 各國
  • 各國分析

第11章 南美的中樞神經系主導療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各類藥物
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各流通管道
    • 各國
  • 各國分析

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢、市場展開

第14章 競爭情形

  • 競爭預測
  • 全球企業簡介
    • Eli Lilly and Company Ltd.
    • Merck & Co. Inc.
    • AstraZeneca PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Biogen Inc.
    • Pfizer Inc.
    • GlaxoSmithKline PLC
    • Otsuka Holdings Co. Ltd.
    • Johnson & Johnson Services Inc.
    • Sanofi SA
    • Bristol Myers Squibb Pharmaceuticals Ltd.
    • Bayer AG
    • Amgen Inc.

第15章 策略性建議

第16章 關於本公司、免責聲明

簡介目錄
Product Code: 7322

The global central nervous system therapeutics market is anticipated to grow at a strong CAGR during the forecast period, 2023-2027. Factors such as the rise in prevalence of central nervous system disorders and advancements in therapeutics and diagnostics of central nervous system disorders are driving the demand for the global central nervous system therapeutics market. Growing diagnosis rates in developed and emerging economies are presenting a large patient pool that requires treatment. Also, the initiatives by the government authorities, healthcare systems, non-profit organizations, and market players to create awareness about neurological disorders are further expected to support the growth of the global central nervous system therapeutics market in the forecast period.

The global central nervous system therapeutics market is segmented into drug class, application, route of administration, end user, distribution channels, regional distribution, and competitive landscape. Based on application, the market is fragmented into neurovascular diseases, mental health and trauma, neurodegenerative diseases, infectious diseases, cns cancer, and others. Neurodegenerative diseases are expected to capture the highest market share during the forecast period, 2023-2027. The high cost of treatment of neurodegenerative diseases and the increased prevalence of neurodegenerative diseases such as Parkinson's disease, multiple sclerosis, and Alzheimer's disease are driving the segment demand.

North America is expected to dominate the global central nervous system therapeutics market during the forecast period. The presence of key market players in the region and the initiatives taken by market players to develop new technologies are infleuncing the market demand. Also, the rising incidence of mental health conditions and neurological disorders is expected to propel the market demand in the forecast period.

The major market players operating in the global central nervous system therapeutics market are: Eli Lilly and Company Ltd., Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., GlaxoSmithKline PLC, Otsuka Holdings Co. Ltd., Johnson & Johnson Services Inc., Sanofi SA, Bristol Myers Squibb Pharmaceuticals Ltd., Bayer AG, Amgen Inc., among others.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of Global central nervous system therapeutics market from 2017 to 2021.
  • To estimate and forecast the market size of Global central nervous system therapeutics market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global central nervous system therapeutics market based on drug class, application, route of administration, end user, distribution channel, and regional distribution.
  • To identify dominant region or segment in the global central nervous system therapeutics market.
  • To identify drivers and challenges for global central nervous system therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global central nervous system therapeutics market.
  • To identify and analyze the profile of leading players operating in global central nervous system therapeutics market.
  • To identify key sustainable strategies adopted by market players in global central nervous system therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global central nervous system therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Central nervous system therapeutics manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of central nervous system therapeutics and services and other stakeholders
  • Organizations, forums, and alliances related to central nervous system therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global central nervous system therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Class:

  • Analgesics
  • Anesthetics
  • Anticonvulsants
  • Antiepileptics
  • Anti-Parkinson Agents
  • Others

Market, By Application:

  • Neurovascular Diseases
  • Mental Health and Trauma
  • Neurodegenerative Diseases
  • Infectious Diseases
  • CNS Cancer
  • Others

Market, By Route of Administrations:

  • Oral
  • Parenteral
  • Others

Market, By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global central nervous system therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Central Nervous System Therapeutics Market

4. Executive Summary

5. Voice of Customer

6. Global Central Nervous System Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiepileptics, Anti-Parkinson Agents, Others)
    • 6.2.2. By Application (Neurovascular Diseases, Mental Health and Trauma, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others)
    • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 6.2.4. By End Users (Hospitals, Clinics, Diagnostic Laboratories, Others)
    • 6.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 6.2.6. By Company (2021)
    • 6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Product Market Map

7. North America Central Nervous System Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By End Users
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Central Nervous System Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End Users
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Central Nervous System Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End Users
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Central Nervous System Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End Users
        • 7.3.3.2.5. By Distribution Channel

8. Europe Central Nervous System Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By End Users
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country (France; Germany; UK; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End Users
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End Users
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End Users
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End Users
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End Users
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Central Nervous System Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By End Users
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country (China; India; Japan; South Korea; Australia)
  • 8.3 Asia-Pacific: Country Analysis
    • 8.3.1 China Central Nervous System Therapeutics Market Outlook
      • 8.3.1.1 Market Size & Forecast
        • 8.3.1.1.1 By Value
      • 8.3.1.2 Market Share & Forecast
        • 8.3.1.2.1 By Drug Class
        • 8.3.1.2.2 By Application
        • 8.3.1.2.3 By Route of Administration
        • 8.3.1.2.4 By End Users
        • 8.3.1.2.5 By Distribution Channel
    • 8.3.2 India Central Nervous System Therapeutics Market Outlook
      • 8.3.2.1 Market Size & Forecast
        • 8.3.2.1.1 By Value
      • 8.3.2.2 Market Share & Forecast
        • 8.3.2.2.1 By Drug Class
        • 8.3.2.2.2 By Application
        • 8.3.2.2.3 By Route of Administration
        • 8.3.2.2.4 By End Users
        • 8.3.2.2.5 By Distribution Channel
    • 8.3.3 Japan Central Nervous System Therapeutics Market Outlook
      • 8.3.3.1 Market Size & Forecast
        • 8.3.3.1.1 By Value
      • 8.3.3.2 Market Share & Forecast
        • 8.3.3.2.1 By Drug Class
        • 8.3.3.2.2 By Application
        • 8.3.3.2.3 By Route of Administration
        • 8.3.3.2.4 By End Users
        • 8.3.3.2.5 By Distribution Channel
    • 8.3.4 South Korea Central Nervous System Therapeutics Market Outlook
      • 8.3.4.1 Market Size & Forecast
        • 8.3.4.1.1 By Value
      • 8.3.4.2 Market Share & Forecast
        • 8.3.4.2.1 By Drug Class
        • 8.3.4.2.2 By Application
        • 8.3.4.2.3 By Route of Administration
        • 8.3.4.2.4 By End Users
        • 8.3.4.2.5 By Distribution Channel
    • 8.3.5 Australia Central Nervous System Therapeutics Market Outlook
      • 8.3.5.1 Market Size & Forecast
        • 8.3.5.1.1 By Value
      • 8.3.5.2 Market Share & Forecast
        • 8.3.5.2.1 By Drug Class
        • 8.3.5.2.2 By Application
        • 8.3.5.2.3 By Route of Administration
        • 8.3.5.2.4 By End Users
        • 8.3.5.2.5 By Distribution Channel

10. Middle East and Africa Central Nervous System Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By End Users
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country (UAE; Saudi Arabia; South Africa)
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Central Nervous System Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End Users
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Central Nervous System Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End Users
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Central Nervous System Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End Users
        • 10.3.3.2.5. By Distribution Channel

11. South America Central Nervous System Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Application
    • 11.2.3. By Route of Administration
    • 11.2.4. By End Users
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country (Brazil; Argentina; Colombia)
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Central Nervous System Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By End Users
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Argentina Central Nervous System Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By End Users
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. Colombia Central Nervous System Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Drug Class
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By End Users
        • 11.3.3.2.6. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Eli Lilly and Company Ltd.
    • 14.2.2. Merck & Co. Inc.
    • 14.2.3. AstraZeneca PLC
    • 14.2.4. Novartis AG
    • 14.2.5. Teva Pharmaceutical Industries Ltd.
    • 14.2.6. F. Hoffmann-La Roche AG
    • 14.2.7. Biogen Inc.
    • 14.2.8. Pfizer Inc.
    • 14.2.9. GlaxoSmithKline PLC
    • 14.2.10. Otsuka Holdings Co. Ltd.
    • 14.2.11. Johnson & Johnson Services Inc.
    • 14.2.12. Sanofi SA
    • 14.2.13. Bristol Myers Squibb Pharmaceuticals Ltd.
    • 14.2.14. Bayer AG
    • 14.2.15. Amgen Inc.

15. Strategic Recommendations

16. About Us & Disclaimer